Search Site

Trends banner

‘Wadeem’ sold out for $1.49bn

This is the highest Abu Dhabi real-estate release to date.

Tesla Q2 sales down 13.5%

Shares rally after the disclosure, better than some forecasts.

TomTom cuts 300 jobs

The firm said it was realigning its organization as it embraces AI.

Aldar nets $953m in sales at Fahid

Aldar said 42 percent of the buyers are under the age of 45.

Qualcomm to Alphawave for $2.4 bn

The deal makes Alphawave the latest tech company to depart London.

AstraZeneca to move to Dubai Science Park with new sustainable offices ahead of COP28

AstraZeneca plans to construct sustainable offices at Dubai Science Park.
  • Set to open in Q3 2023, the move is part of the biopharmaceutical giant’s global green agenda
  • The company recently held its first multilateral engagement on health and climate at COP27

Dubai, UAE – In line with this year’s focus on sustainability in the UAE, AstraZeneca has announced plans to construct sustainable offices at Dubai Science Park, a member of TECOM Group.

Set to open in Q3 2023, the move is part of the biopharmaceutical giant’s global green agenda and in-line with “We the UAE 2031” vision and the Year of Sustainability.

The new office design, construction, and materials will meet platinum standards in Leadership in Energy and Environmental Design (LEED) set out by the U.S. Green Building Council (USGBC). The Green Building Classification System is one of the most widely used worldwide and a marker of healthy, efficient, and carbon-saving buildings.

AstraZeneca is a champion of the Sustainable Markets Initiative (SMI) Health Systems Task Force – a public-private partnership committed to accelerating the delivery of net zero healthcare systems. The company recently held its first multilateral engagement on health and climate at COP27, bringing together members of the SMI, the World Health Organisation (WHO) and the Commonwealth Secretariat to announce new joint action to accelerate net zero healthcare in three areas: supply chains, patient care pathways, and clinical trials.